Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid
https://investor.lilly.com/releasedetail.cfm?ReleaseID=1008267
Lilly to acquire CoLucid for $46.50 per share or approximately $960 million
LLY CLCD
ATHX
through its Belgian subsidiary, ReGenesys BVBA (ReGenesys), it has entered into an agreement with a global leader in the animal health business segment to evaluate the cell therapy technology for application in a non-disclosed animal health area. Under the terms of the agreement, ReGenesys will receive an initial payment in exchange for an exclusive period to evaluate the cell therapy technology with an option to negotiate for a license for the development and commercialization of the technology for this area. Additional details were not disclosed.
FGEN
A la espera de más datos el viernes, buenos resultados para cáncer de páncreas.
LIFE
FDA Grants fast track designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris
Esta se deshincha tras los pre, pero como le quitan también el hold no me atrevo a meterle corto por ahora.
Gild y la nacionalización de farmas
Dr. Mark Trusheim of MIT’s Center of Biomedical Innovation, have taken the concept of biopharma acquisitions and applied it intriguingly into a plan for the US government to obtain access to important drugs. The drugs in question are the hepatitis C cures, Harvoni and Sovaldi, both sold by Gilead.
CASC
De ayer:
Mark Lampert says resigning from Cascadian Therapeutics' board
Mark Lampert owns 19.99 percent stake in Cascadian Therapeutics Inc as of January 5 Source: (bit.ly/2iyL0LT)
http://www.reuters.com/article/idUSFWN1F70UV?type=companyNews&feedType=RSS
pues cuando todo se pone muy mal es momento de comprar :)
2017 Shaping Up Nicely For Horizon Pharma
http://seekingalpha.com/article/4037610-2017-shaping-nicely-horizon-pharma
HZNP
